988 related articles for article (PubMed ID: 9382747)
1. Infections with Pseudomonas aeruginosa in patients with cystic fibrosis.
Tümmler B; Bosshammer J; Breitenstein S; Brockhausen I; Gudowius P; Herrmann C; Herrmann S; Heuer T; Kubesch P; Mekus F; Römling U; Schmidt KD; Spangenberg C; Walter S
Behring Inst Mitt; 1997 Feb; (98):249-55. PubMed ID: 9382747
[TBL] [Abstract][Full Text] [Related]
2. Fcgamma receptor IIA genotype and susceptibility to P. aeruginosa infection in patients with cystic fibrosis.
De Rose V; Arduino C; Cappello N; Piana R; Salmin P; Bardessono M; Goia M; Padoan R; Bignamini E; Costantini D; Pizzamiglio G; Bennato V; Colombo C; Giunta A; Piazza A
Eur J Hum Genet; 2005 Jan; 13(1):96-101. PubMed ID: 15367919
[TBL] [Abstract][Full Text] [Related]
3. Pseudomonas aeruginosa chromosomal beta-lactamase in patients with cystic fibrosis and chronic lung infection. Mechanism of antibiotic resistance and target of the humoral immune response.
Ciofu O
APMIS Suppl; 2003; (116):1-47. PubMed ID: 14692154
[TBL] [Abstract][Full Text] [Related]
4. Lung infection with alginate-producing, mucoid Pseudomonas aeruginosa in cystic fibrosis.
Pedersen SS
APMIS Suppl; 1992; 28():1-79. PubMed ID: 1449848
[TBL] [Abstract][Full Text] [Related]
5. Lipopolysaccharide (LPS), LPS-immune complexes and cytokines as inducers of pulmonary inflammation in patients with cystic fibrosis and chronic Pseudomonas aeruginosa lung infection.
Kronborg G
APMIS Suppl; 1995; 50():1-30. PubMed ID: 7756034
[TBL] [Abstract][Full Text] [Related]
6. Familial concordance of phenotype and microbial variation among siblings with CF.
Picard E; Aviram M; Yahav Y; Rivlin J; Blau H; Bentur L; Avital A; Villa Y; Schwartz S; Kerem B; Kerem E
Pediatr Pulmonol; 2004 Oct; 38(4):292-7. PubMed ID: 15334505
[TBL] [Abstract][Full Text] [Related]
7. Strategies of Pseudomonas aeruginosa to colonize and to persist in the cystic fibrosis lung.
Kubesch P; Lingner M; Grothues D; Wehsling M; Tümmler B
Scand J Gastroenterol Suppl; 1988; 143():77-80. PubMed ID: 3133755
[TBL] [Abstract][Full Text] [Related]
8. Clonal epidemiology of Pseudomonas aeruginosa in cystic fibrosis.
Cramer N; Wiehlmann L; Tümmler B
Int J Med Microbiol; 2010 Dec; 300(8):526-33. PubMed ID: 20951087
[TBL] [Abstract][Full Text] [Related]
9. Rationale for development of immunotherapies that target mucoid Pseudomonas aeruginosa infection in cystic fibrosis patients.
Pier GB
Behring Inst Mitt; 1997 Feb; (98):350-60. PubMed ID: 9382760
[TBL] [Abstract][Full Text] [Related]
10. Mucoid Pseudomonas aeruginosa isolates maintain the biofilm formation capacity and the gene expression profiles during the chronic lung infection of CF patients.
Lee B; Schjerling CK; Kirkby N; Hoffmann N; Borup R; Molin S; Høiby N; Ciofu O
APMIS; 2011 Apr; 119(4-5):263-74. PubMed ID: 21492226
[TBL] [Abstract][Full Text] [Related]
11. Dynamics of adaptive microevolution of hypermutable Pseudomonas aeruginosa during chronic pulmonary infection in patients with cystic fibrosis.
Hoboth C; Hoffmann R; Eichner A; Henke C; Schmoldt S; Imhof A; Heesemann J; Hogardt M
J Infect Dis; 2009 Jul; 200(1):118-30. PubMed ID: 19459782
[TBL] [Abstract][Full Text] [Related]
12. Poor clinical outcomes associated with a multi-drug resistant clonal strain of Pseudomonas aeruginosa in the Tasmanian cystic fibrosis population.
Bradbury R; Champion A; Reid DW
Respirology; 2008 Nov; 13(6):886-92. PubMed ID: 18811887
[TBL] [Abstract][Full Text] [Related]
13. Vaccination promotes TH1-like inflammation and survival in chronic Pseudomonas aeruginosa pneumonia. A new prophylactic principle.
Johansen HK; Cryz SJ; Hougen HP; Moser C; Høiby N
Behring Inst Mitt; 1997 Feb; (98):269-73. PubMed ID: 9382750
[TBL] [Abstract][Full Text] [Related]
14. Relations between the frequency of the DeltaF 508 mutation and the course of pulmonary disease in cystic fibrosis patients infected with Pseudomonas aeruginosa.
Rosenecker J
Eur J Med Res; 2000 Aug; 5(8):356-9. PubMed ID: 10958769
[TBL] [Abstract][Full Text] [Related]
15. Effective prevention of Pseudomonas aeruginosa cross-infection at a cystic fibrosis centre - results of a 10-year prospective study.
Wiehlmann L; Cramer N; Ulrich J; Hedtfeld S; Weissbrodt H; Tümmler B
Int J Med Microbiol; 2012 Mar; 302(2):69-77. PubMed ID: 22196973
[TBL] [Abstract][Full Text] [Related]
16. Emergence and persistence of Pseudomonas aeruginosa in the cystic fibrosis airway.
Fick RB; Sonoda F; Hornick DB
Semin Respir Infect; 1992 Sep; 7(3):168-78. PubMed ID: 1475541
[TBL] [Abstract][Full Text] [Related]
17. Pseudomonas aeruginosa infection in cystic fibrosis. Bactericidal effect of serum from normal individuals and patients with cystic fibrosis on P. aeruginosa strains from patients with cystic fibrosis or other diseases.
Holby N; Olling S
Acta Pathol Microbiol Scand C; 1977 Apr; 85(2):107-14. PubMed ID: 404841
[TBL] [Abstract][Full Text] [Related]
18. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience.
Hansen CR; Pressler T; Høiby N
J Cyst Fibros; 2008 Nov; 7(6):523-30. PubMed ID: 18693078
[TBL] [Abstract][Full Text] [Related]
19. Relationship between cystic fibrosis respiratory tract bacterial communities and age, genotype, antibiotics and Pseudomonas aeruginosa.
Klepac-Ceraj V; Lemon KP; Martin TR; Allgaier M; Kembel SW; Knapp AA; Lory S; Brodie EL; Lynch SV; Bohannan BJ; Green JL; Maurer BA; Kolter R
Environ Microbiol; 2010 May; 12(5):1293-303. PubMed ID: 20192960
[TBL] [Abstract][Full Text] [Related]
20. Nonopsonic antibodies in cystic fibrosis. Pseudomonas aeruginosa lipopolysaccharide-specific immunoglobulin G antibodies from infected patient sera inhibit neutrophil oxidative responses.
Eichler I; Joris L; Hsu YP; Van Wye J; Bram R; Moss R
J Clin Invest; 1989 Dec; 84(6):1794-804. PubMed ID: 2512330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
